

Syngene inks drug discovery agreement with GSK

27 March 2018 | News

Biocon's Syngene will set-up a customised discovery research laboratory to support projects across several therapeutic areas



Biocon's contract research arm Syngene International inked a drug discovery agreement with global drug firm GSK.

The multi-year R&D agreement between the two companies will focus on accelerating the discovery of new drug candidates using Syngene's discovery services platforms.

As part of the collaboration, Syngene will set-up a customised discovery research laboratory to support projects across several therapeutic areas.

A team of Syngene scientists will work closely with GSK's global R&D teams on discovery research projects to identify new drug candidates with the potential to address some of the world's most pressing healthcare needs.

Syngene started offering discovery services to global R&D focused organisations from 1994 onwards. Over the years, it has consolidated its position in offering integrated discovery, development and manufacturing services across small and large molecules within both the pharmaceutical and biotechnology industries.